Castleark Management’s TG Therapeutics TGTX Stock Holding History

Castleark Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.3M	Buy	+150,990	New	+$6.18M	0.22%	111
2025 Q4	–	Sell	-140,316	Closed	-$5.07M	–	338
2025 Q3	$5.07M	Sell	140,316 -110,114	-44%	-$3.63M	0.14%	146
2025 Q2	$9.01M	Buy	250,430 +13,340	+6%	+$497K	0.27%	51
2025 Q1	$9.35M	Buy	237,090 +25,720	+12%	+$865K	0.32%	41
2024 Q4	$6.36M	Buy	211,370 +42,560	+25%	+$1.22M	0.22%	110
2024 Q3	$3.95M	Buy	+168,810	New	+$3.69M	0.16%	138
2023 Q3	–	Sell	-90,980	Closed	-$2.26M	–	312
2023 Q2	$2.26M	Buy	+90,980	New	+$2.35M	0.1%	158
2021 Q4	–	Sell	-20,211	Closed	-$673K	–	363
2021 Q3	$673K	Sell	20,211 -186,550	-90%	-$5.77M	0.03%	236
2021 Q2	$8.02M	Sell	206,761 -10,870	-5%	-$427K	0.27%	102
2021 Q1	$10.5M	Buy	217,631 +65,715	+43%	+$3.16M	0.38%	81
2020 Q4	$7.9M	Buy	151,916 +26,706	+21%	+$902K	0.3%	88
2020 Q3	$3.35M	Buy	+125,210	New	+$2.88M	0.13%	149

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Castleark Management's TGTX Position: Q2 2026 in Review

Castleark Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 150,990 shares worth $8.3M. The stake represents 0.22% of the portfolio and ranks #111 among its holdings. This is a return to the name: Castleark Management previously reported a position in TGTX as recently as Q3 2025.

Castleark Management first reported a position in TGTX in Q3 2020 and has held it in 12 quarters since. The position peaked at $10.5M in Q1 2021. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Castleark Management held 150,990 shares of TG Therapeutics worth $8.3M as of Q2 2026.
TG Therapeutics was a new Castleark Management position in Q2 2026.
TG Therapeutics made up 0.22% of Castleark Management's portfolio in Q2 2026, its #111 holding.
Castleark Management first reported a position in TG Therapeutics in Q3 2020 and has held it in 12 quarters since.
Castleark Management's TG Therapeutics position peaked at $10.5M in Q1 2021.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.